Evidence map›Paper›PMID 40249168›Full record

Observational studyBrain and behavior2025

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy.

Isaac Cowley, Simon Erridge, Arushika Aggarwal, Lilia Evans, Madhur Varadpande, Evonne Clarke, Katy McLachlan, Ross Coomber, Augustin Iqbal, James J Rucker and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Isaac CowleyImperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
Simon ErridgeImperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-5871-6501
Arushika AggarwalImperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
Lilia EvansImperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID https://orcid.org/0009-0001-5337-2620
Madhur VaradpandeImperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
Evonne ClarkeCuraleaf Clinic, London, UK.
Katy McLachlanCuraleaf Clinic, London, UK.
Ross CoomberCuraleaf Clinic, London, UK.
Augustin IqbalCuraleaf Clinic, London, UK.
James J RuckerCuraleaf Clinic, London, UK.
Mark W WeatherallCuraleaf Clinic, London, UK.
Mikael H SodergrenImperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA third of epilepsy patients fail to enter seizure remission despite optimal therapeutic management. Cannabis-based medicinal products (CBMPs) have shown promise as a potential therapy. However, a paucity of high-quality literature regarding CBMPs' efficacy and safety profile means further investigation is needed. The study aimed to examine changes in epilepsy-specific and general health-related quality of life (HRQoL) patient-reported outcome measures (PROMs) in individuals with treatment-resistant epilepsy.

methodsA case series of patients with epilepsy from the UK Medical Cannabis Registry analyzed changes in Quality of Life in Epilpesy-31 (QOILE-31), Single-Item Sleep Quality Score (SQS), EQ-5D-5L, Generalized Anxiety Disorder-7 (GAD-7) and Patient Global Impression of Change (PGIC) between baseline, one, three, and six months. Adverse events (AEs) were collected and classified by severity. p < 0.050 was considered statistically significant.

resultsThere were 134 patients included. Improvements were recorded from baseline to one, three, and six months in QOILE-31 and all HRQoL PROMs (p < 0.050). Forty patients (29.85%) reported a minimal clinically important difference in Quality of Life in Epilepsy-31 (QOLIE-31) at six months. There were 18 (13.43%) AEs reported by 5 (3.73%) patients, mainly mild and moderate. DISCUSSION: The proportion of patients achieving a clinically significant change is similar to existing CBMPs in epilepsy literature. AE incidence was lower than similar studies although this may be due to the large proportion (67.16%) of individuals who were not cannabis naïve.

conclusionInitiation of CBMPs was associated with an improvement across all PROMs. CBMPs were well tolerated across the cohort. However, randomized controlled trials are needed to help determine causality. CLINICAL

trial registration

Indexed as

Drug Resistant EpilepsyEpilepsyMedical MarijuanaAdolescentAdultFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresQuality of LifeRegistriesTreatment OutcomeUnited KingdomYoung AdultMedical MarijuanaCannabidiolCannabisEpilepsyΔ9‐tetrahydrocannabinol

Identifiers

PMID40249168
PMCPMC12007016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.